FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context
Therapeutic approaches for acute myeloid leukemia (AML) have witnessed minimal evolution in recent decades, primarily relying on advancements in supportive care and transplantation to drive improvements in overall survival rates. However, treatment with intensive chemotherapy may not be feasible for...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2024-04-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1779621 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849337533532471296 |
|---|---|
| author | Suvir Singh Kunal Jain Jagdeep Singh Nitish Garg Akriti Arora |
| author_facet | Suvir Singh Kunal Jain Jagdeep Singh Nitish Garg Akriti Arora |
| author_sort | Suvir Singh |
| collection | DOAJ |
| description | Therapeutic approaches for acute myeloid leukemia (AML) have witnessed minimal evolution in recent decades, primarily relying on advancements in supportive care and transplantation to drive improvements in overall survival rates. However, treatment with intensive chemotherapy may not be feasible for patients with advanced age or reduced fitness, and outcomes for patients with relapsed/refractory disease continue to be suboptimal. Several agents with a novel mechanism of action have been developed in the past decade and have shown efficacy in patients with both newly diagnosed and relapsed AML. Out of these, several FLT3 (FMS like tyrosine kinase 3) and IDH1/2 (isocitrate dehydrogenase 1/2) inhibitors have received regulatory approval in specific clinical settings and are available for clinical use. This is an actively expanding field with several ongoing clinical trials in advanced phases. We provide a focused narrative review of drugs from these two categories with available clinical data. |
| format | Article |
| id | doaj-art-42c0d33c6071477a8c1723c95b3631f3 |
| institution | Kabale University |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-42c0d33c6071477a8c1723c95b3631f32025-08-20T03:44:39ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292024-04-01450211512610.1055/s-0044-1779621FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian ContextSuvir Singh0https://orcid.org/0000-0003-2067-8567Kunal Jain1Jagdeep Singh2Nitish Garg3Akriti Arora4Department of Clinical Hematology, Dayanand Medical College, Ludhiana, Punjab, IndiaDepartment of Medical Oncology, Dayanand Medical College, Ludhiana, Punjab, IndiaDepartment of Medical Oncology, Dayanand Medical College, Ludhiana, Punjab, IndiaDepartment of Medical Oncology, Dayanand Medical College, Ludhiana, Punjab, IndiaDepartment of Clinical Hematology, Dayanand Medical College, Ludhiana, Punjab, IndiaTherapeutic approaches for acute myeloid leukemia (AML) have witnessed minimal evolution in recent decades, primarily relying on advancements in supportive care and transplantation to drive improvements in overall survival rates. However, treatment with intensive chemotherapy may not be feasible for patients with advanced age or reduced fitness, and outcomes for patients with relapsed/refractory disease continue to be suboptimal. Several agents with a novel mechanism of action have been developed in the past decade and have shown efficacy in patients with both newly diagnosed and relapsed AML. Out of these, several FLT3 (FMS like tyrosine kinase 3) and IDH1/2 (isocitrate dehydrogenase 1/2) inhibitors have received regulatory approval in specific clinical settings and are available for clinical use. This is an actively expanding field with several ongoing clinical trials in advanced phases. We provide a focused narrative review of drugs from these two categories with available clinical data.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1779621myeloidleukemiaFLT3midostauringilteritinibsorafenib |
| spellingShingle | Suvir Singh Kunal Jain Jagdeep Singh Nitish Garg Akriti Arora FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context Indian Journal of Medical and Paediatric Oncology myeloid leukemia FLT3 midostaurin gilteritinib sorafenib |
| title | FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context |
| title_full | FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context |
| title_fullStr | FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context |
| title_full_unstemmed | FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context |
| title_short | FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context |
| title_sort | flt3 and idh1 2 inhibitors for acute myeloid leukemia focused clinical narrative review of forthcoming drugs from an indian context |
| topic | myeloid leukemia FLT3 midostaurin gilteritinib sorafenib |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1779621 |
| work_keys_str_mv | AT suvirsingh flt3andidh12inhibitorsforacutemyeloidleukemiafocusedclinicalnarrativereviewofforthcomingdrugsfromanindiancontext AT kunaljain flt3andidh12inhibitorsforacutemyeloidleukemiafocusedclinicalnarrativereviewofforthcomingdrugsfromanindiancontext AT jagdeepsingh flt3andidh12inhibitorsforacutemyeloidleukemiafocusedclinicalnarrativereviewofforthcomingdrugsfromanindiancontext AT nitishgarg flt3andidh12inhibitorsforacutemyeloidleukemiafocusedclinicalnarrativereviewofforthcomingdrugsfromanindiancontext AT akritiarora flt3andidh12inhibitorsforacutemyeloidleukemiafocusedclinicalnarrativereviewofforthcomingdrugsfromanindiancontext |